SFI
SONN

Susquehanna Fundamental Investments’s Sonnet BioTherapeutics SONN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10
Closed -$63K – 1595
2020
Q3 		$63K Buy
+10
New +$72.1K ﹤0.01% 1313

Other funds holding SONN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna Fundamental Investments's SONN Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Sonnet BioTherapeutics (SONN) in Q4 2020, closing a stake of 10 shares — an estimated $63K sold.

Susquehanna Fundamental Investments first reported a position in SONN in Q3 2020 and held it in 1 quarter. The position peaked at $63K in Q3 2020. 8 funds tracked by Wall St. Rank hold SONN as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Sonnet BioTherapeutics position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 10 Sonnet BioTherapeutics shares in Q4 2020, an estimated $63K.
  • Susquehanna Fundamental Investments first reported a position in Sonnet BioTherapeutics in Q3 2020 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Sonnet BioTherapeutics position peaked at $63K in Q3 2020.
  • 8 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.